Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470248 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1NAAACES2 | |
| SCHEMBL700802 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1NAAACES2 | |
| SCHEMBL3913988 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1NAAACES2 | |
| SCHEMBL9660836 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1NAAACES2 | |
| SCHEMBL700500 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1NAAACES2 | |
| SCHEMBL9660637 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1NAAACES2 | |
| SCHEMBL706907 | 0.98 | — | — | |
| SCHEMBL4241992 | 0.92 | HTT (0.50) | LPAR3LPAR2LPAR1NAAACES2 | |
| SCHEMBL702719 | 0.90 | — | — | |
| SCHEMBL1689825 | 0.88 | LPAR3 (0.50) | LPAR3LPAR2LPAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024074501-A1 | PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS | UNIVERSITE DE POITIERS (FR) | 2024-04-11 | — | — | WO | disclosed |
| EP-2252584-B1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2651828-A1 | PROCESS FOR PREPARING A COMPOSTION OF MIXED PARTICLES CONTAINING ELEMENTS FROM COLUMNS 13 AND 15 | Centre National De La Recherche Scientifique CNRS (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-8445292-B2 | Compounds and methods for rapid labeling of N-glycans | PROZYME, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2012080425-A1 | PROCESS FOR PREPARING A COMPOSTION OF MIXED PARTICLES CONTAINING ELEMENTS FROM COLUMNS 13 AND 15 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-06-21 | — | — | WO | disclosed |
| US-20120107942-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8163910-B2 | Amide-substituted xanthene dyes | ELITECH HOLDING B.V. (NL) | 2012-04-24 | — | — | US | disclosed |
| US-8124792-B2 | Compounds and methods for rapid labeling of N-glycans | PROZYME, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2252584-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | Prozyme, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090258437-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-6204222-B1 | SUITABLE AS HERBICIDES AND FOR DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-20 | — | — | US | disclosed |
| EP-0637298-B1 | SUBSTITUTED CYCLOHEXENE-1,2-BICARBOXYLIC ACID DERIVATIVES AND RAW MATERIALS FOR PRODUCING THEM | BASF AG (DE) | 1999-03-31 | — | — | EP | disclosed |
| US-5817603-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | disclosed |
| EP-0837864-A1 | NOVEL QUINOXALINE- AND QUINOXALINYLALKANE-PHOSPHONIC ACIDS | Novartis AG (CH) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997003079-A1 | NOVEL QUINOXALINE- AND QUINOXALINYLALKANE-PHOSPHONIC ACIDS | NOVARTIS AG (CH) | 1997-01-30 | — | — | WO | disclosed |
| EP-0705835-A1 | Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
| EP-0705834-A1 | Quinoxaline-2,3-diones with an azaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
| WO-1993022280-A1 | SUBSTITUTED CYCLOHEXENE-1,2-BICARBOXYLIC ACID DERIVATIVES AND RAW MATERIALS FOR PRODUCING THEM | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-11 | — | — | WO | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0233121-A1 | Process for removing lead from rare earths | RHONE-POULENC CHIMIE (FR) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258437-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | B3GNT2, FUT5, FUT6 | LPAR3 1908/4885LPAR2 3009/4885LPAR1 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.